
PathoVax LLC is a Johns Hopkins start-up biotechnology company headquartered in Baltimore, Maryland. Founded in 2014, the company has been focused on different medical applications for its proprietary Papillomavirus Virus-like Particle (VLP) platform.
Management & Operations Team
Joshua Wang Ph.D.
Co-Founder & CEO
Wenbin Lai Ph.D., MBA
Chemistry, Manufacturing & Controls Advisor (Singapore)

Dr Robert (‘”Bob”) Becker, PhD MBA is an experienced executive with a proven history in fostering partnerships with product development, cGMP manufacturing, clinical development and regulatory affairs
Robert "Bob" Becker Ph.D., MBA
Business Management

Mr Jay Nadkarni joins PathoVax with 20+ years of experience in all aspects of new product commercialization and licensing; and has to his credit many successful licensing deals brought to fruition. He has a commendable track record in Innovation Management, Licensing, Business Development, and Technology Transfers for Biopharmaceuticals, Biologics, and Rx / OTC Pharmaceuticals all over the world with emphasis on Tier-1&2 Emerging Markets
Jay Nadkarni, MBA
Partnerships
Business Advisory Board

Robert Silverman
Chairman of Business Advisory Board

Eric Richman, MBA
Business Advisor

Roger Pomerantz M.D., FACP
Business Advisor

Solomon Langermann, Ph.D
Business Advisor
Scientific, Clinical Advisory Board, and Collaborators

Richard Roden, Ph.D
Co-director of Viral Oncology, Johns Hopkins School of medicine

Reinhard Kirnbauer, MD
Director of Viral Oncology,
Medical University Vienna

Warner Huh, M.D
Professor and Division Director of the Division of Gynecologic Oncology at the University of Alabama at Birmingham.
